Impact of

Akvilė Mikulskienė, Roberta Vadeikienė, Aurelija Vegienė, Rasa Ugenskienė, Elona Juozaityte, Evaldas Padervinskis

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akvilė MikulskienėDepartment of Otorhinolaryngology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0009-0004-9838-1186

Roberta VadeikienėOncology Research Laboratory, Institute of Oncology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.

Aurelija VegienėDepartment of Otorhinolaryngology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.

Rasa UgenskienėOncology Research Laboratory, Institute of Oncology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.

Elona JuozaityteInstitute of Oncology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0000-0001-6695-7786

Evaldas PadervinskisDepartment of Otorhinolaryngology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.ORCID 0009-0000-4883-0642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laryngeal cancer is a relatively uncommon malignancy with predisposing genetic factors that remain unclear. Single-nucleotide polymorphisms (SNPs) in genes involved in innate immune signaling may contribute to the development and progression of laryngeal carcinoma. This study aimed to evaluate the association of

Indexed as

Carcinoma, Squamous CellLaryngeal NeoplasmsMyeloid Differentiation Factor 88Polymorphism, Single NucleotideToll-Like Receptor 4AgedCase-Control StudiesDisease ProgressionFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedPrognosisRetrospective StudiesMYD88 protein, humanMyeloid Differentiation Factor 88TLR4 protein, humanToll-Like Receptor 4laryngeal cancerMYD88SNPTLR4

Identifiers

PMID42278290

DOI10.3390/ijms27114760

PMCPMC13256836

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.